Affimed Stock (NASDAQ:AFMD)
Previous Close
$2.64
52W Range
$2.61 - $8.95
50D Avg
$3.38
200D Avg
$4.76
Market Cap
$39.90M
Avg Vol (3M)
$102.33K
Beta
2.10
Div Yield
-
AFMD Company Profile
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
AFMD Performance
Peer Comparison
Ticker | Company |
---|---|
XFOR | X4 Pharmaceuticals, Inc. |
MREO | Mereo BioPharma Group plc |
ADCT | ADC Therapeutics SA |
DAWN | Day One Biopharmaceuticals, Inc. |
PDSB | PDS Biotechnology Corporation |
ADAP | Adaptimmune Therapeutics plc |
CRVS | Corvus Pharmaceuticals, Inc. |
APTO | Aptose Biosciences Inc. |
TERN | Terns Pharmaceuticals, Inc. |
INZY | Inozyme Pharma, Inc. |
AGEN | Agenus Inc. |
EFTR | eFFECTOR Therapeutics, Inc. |
LPTX | Leap Therapeutics, Inc. |
PIRS | Pieris Pharmaceuticals, Inc. |
HEPA | Hepion Pharmaceuticals, Inc. |
ELEV | Elevation Oncology, Inc. |